Remember, Remember the Fifth of November: Biotech’s Fireworks, Sparks and Slow Burns
Updated: Nov 8
Remember, remember the fifth of November—the night when bonfires burn, fireworks light the sky and everyone looks up to see what will explode next. Biotech has its own fireworks display. This year brought headline-grabbing deals, clinical breakthroughs, new approvals and renewed excitement around AI, RNA, gene editing and next-generation therapies. But, as with any fireworks show, not everything that launches reaches the same height. Some ideas popped spectacularly, some sparkled quietly, and others fizzled before they could make an impact.
For biotech insiders and investors, the more important question is not simply what created the biggest bang. It is which developments created lasting value—and which were only temporary flashes in the night sky.
What popped
The biggest “rockets” were the transactions and clinical milestones that changed expectations.
M&A remained one of the clearest signals of investor and pharmaceutical confidence. Large companies continued looking for differentiated science, commercial growth opportunities and technologies that could address future patent expiries. Deal activity focused on areas including GLP-1 expansion, RNA, antibody-drug conjugates and gene editing.
The IPO market also showed signs of recovery. However, today’s public-market investors are demanding more than an attractive scientific narrative. Companies increasingly need credible clinical evidence, realistic development plans, disciplined cash management and a clear path toward partnering or commercialization.
AI continued to attract attention, but the conversation became more practical. The key question is no longer whether AI will transform drug discovery. It is whether a company’s technology can produce better candidates, shorten development timelines, improve trial design or reduce costs in a measurable way.

What sparkled quietly
Some of the most important progress did not make the biggest headlines.
Manufacturing, process development, clinical operations and regulatory execution remain essential value drivers. A promising molecule cannot create value if it cannot be manufactured reliably, tested efficiently or scaled commercially.
For investors, these less visible capabilities can distinguish a durable biotech from a headline-driven company. Quality systems, clean datasets, reproducible processes and credible CMC plans may not create fireworks, but they reduce execution risk—the risk most likely to determine whether a program reaches the market.

What fizzled out
The year also reinforced a difficult lesson: scientific excitement does not automatically translate into shareholder value.
Some programs failed to meet clinical endpoints. Others faced safety concerns, financing pressure or increased competition. Several technology categories became crowded, making differentiation more difficult for companies with similar platforms and limited clinical validation.
The market has therefore become less forgiving. Investors are asking:
Is the biology convincing?
Is the clinical benefit meaningful?
Is the target product profile differentiated?
Can the company reach its next value inflection point?
Will additional capital create value or simply extend the runway?
A strong presentation is no longer enough. The data, development strategy and capital plan must work together.
Fireworks Night is built around anticipation: the fuse is lit, the crowd waits and everyone watches for the next burst of colour. Biotech works in much the same way. The headline event may be a clinical readout, regulatory approval or major acquisition, but the real preparation happens long before the launch.
As this year’s fireworks fade, investors and biotech leaders should look beyond the brightest flashes. The companies most likely to create lasting value may be those quietly building stronger data, clearer strategies, scalable manufacturing and disciplined capital plans.
The next big bang may already be taking shape—but first, someone has to set the fuse.
I realise this Fireworks Night take will be “out of date” within a day, but it felt like a fun lens on a year that’s been anything but dull for biotech.
If any of these sparks resonate with what you’re seeing in your own portfolio or pipeline, feel free to reach out — I’m always happy to compare notes and see whether I can help - Enjoy the Evening!




Comments